Investing.com -- Organogenesis Holdings Inc. (NASDAQ:ORGO) shares rose 20% Tuesday after the company announced its PuraPly AM product achieved the primary endpoint in a randomized controlled trial for ...

An analyst updated Organogenesis' price target. Competitor Integra LifeSciences said Tuesday it was recalling a product. Organogenesis has a knee osteoarthritis therapy, ReNu, in phase 3 trials.

Organogenesis shares have dropped ~42% since my last 'Hold' rating, reflecting ongoing challenges in its core business. Q1 2025 earnings disappointed, with the dominant Advanced Wound Care segment ...

The market has shown robust performance, rising 3.1% over the last week and 27% over the past year, with earnings expected to grow by 16% annually in the coming years. In light of these conditions, ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

For the full-year 2025, management updated guidance to project net revenue of $500 million to $525 million, with Advanced Wound Care products expected between $470 million and $490 million and ...

The latest price target for Organogenesis Holdings (NASDAQ:ORGO) was reported by Cantor Fitzgerald on August 8, 2025. The analyst firm set a price target for $9.00 expecting ORGO to rise to within 12 ...

Clinical Development Program Appropriate for Rolling BLA . Submission Expected by the End of 2025. CANTON, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (N ...

Robust 218-patient RCT demonstrates statistically superior frequency of wound closure at 12 weeks compared to standard of care (p=.04) Organogenesis believes published study satisfies requirements for ...